A number of molecules combined 5-HT1A agonist and SSRI have been developed, and Vilazodone is the first compound that was approved on 21 January 2011 by the US Food and Drug Administration (FDA) for the treatment of Major Depressive Disorder (MDD). Here, HTR1A is linked to major depressive disorder.